The RadTox™ Test is intended to offer an early assessment of patient response to radiotherapy. It is a simple blood test to monitor tumor response & progression after treatment by monitoring changes in cell-free circulating DNA (cfDNA) levels. To ensure effective patient care, it is necessary for doctors to know early on whether a patient is responding to treatment to mitigate adverse events.

The RadTox™ Test is based on DiaCarta’s proprietary QuantiDNA™ Direct cfDNA Test technology. It directly measures the concentration of circulating cfDNA in blood sample, and is used to monitor the cfDNA levels during treatment, such as radiation therapy (radiotherapy), chemotherapy, immunotherapy, and other anti-cancer therapies

Test Procedure:
  • RadTox Assay are based on SuperbDNATM technology, which improves the bDNA technology to make it more sensitive for detecting target DNA or RNA molecules. Particularly, this assays quantify only human or other primate DNAs.
  • The bDNA technology was developed to capture target DNA or RNA molecules using a series of hybridization probes to amplify chemical signals associated with the targets and quantify the signals that are proportional to the target quantity. 
  • Based on the bDNA technology, SuperbDNATM technology uses new probe set designs that result in increased amplification of the target gene signal.  
Fig: SuperbDNA technology

Sample collection:

2 blood samples must be collected. The first sample is collected before the treatment and the second is collected 24-48 hours after radiotherapy.

This test can be performed on:

  • Luminex MAGPIX
  • Luminometer

RadTox™ Assay Fulfills an Unmet Need

The Radiotherapy Toxicity Measurement Assay is developed to monitor tissue damage-related toxicity from radiation therapy. The measurement fulfills an unmet medical need in cancer radiation therapy by enabling the direct monitoring of side effect severity within days of radiation treatment initiation.  

The assay would allow dose escalation to tumors in less sensitive patients, aid development of radiotoxicity mitigators, and reduce over-treatment risk for sensitive patients.  

The radiotherapy toxicity assay provides fast, cost-effective quantitation of liquid biopsy cfDNA sample from cancer patients before and after radiation therapy and provides patient information for estimates of dosage usage and general radiation resistance.